Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

Parkinson's disease is a complex neurodegenerative disorder for which both rare and
common genetic variants contribute to disease risk, onset, and progression. Mutations in …

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
degeneration of the substantia nigra pars compacta and by accumulation of α-synuclein in …

ABSTRACT A substantial proportion of risk for Parkinson's disease (PD) is driven by
genetics. Progress in understanding the genetic basis of PD has been significant. So far …

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance
pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder. It is
caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an …

Parkinson's disease is a progressive neurodegenerative condition associated with the
deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease …

Parkinson's disease (PD) is a growing burden worldwide, and there is no reliable biomarker
used in clinical routines to date. Cerebrospinal fluid (CSF) is routinely collected in patients …